Hemogenyx Pharmaceuticals PLC Announces Presentation at CBD S&T Conference

August 28, 2024 2:00 AM

Hemogenyx Pharmaceuticals plc (LSE:HEMO), the clinical-stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to announce its participation in the 2024 Chemical and Biological Defense Science & Technology ("CBD S&T") Conference, which will be held on December 2-5, 2024, in Fort Lauderdale, FL.The Company competed for a presentation slot and was invited to present its work on its proprietary Chimeric Bait...

Read more

Ensysce Biosciences Announces IRB Approval for Key MPAR Study

August 27, 2024 2:30 PM

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has received Investigational Review Board ("IRB") approval of the PF614-MPAR-102 protocol, ‘A Single and Multiple Dose Study to Evaluate the Pharmacokinetics of Oxycodone and PF614 when PF614 capsule...

Read more

Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection

August 27, 2024 8:00 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced receipt of a $14 million multi-year grant from the NIH and National Institute on Drug Abuse (NIDA) for the continued development of PF614-MPAR, an abuse-deterrent opioid with overdose protection that received...

Read more

Indica Labs and Paige Forge Strategic Partnership to Expand Integrated AI for Anatomic Pathology Labs

August 27, 2024 8:00 AM

ALBUQUERQUE, NM and NEW YORK, NY / ACCESSWIRE / August 27, 2024 / Indica Labs, a leading provider of computational pathology software and Paige, a leader in next-generation AI technology have formed a non-exclusive partnership aimed at integrating Paige's Diagnostic AI models into Indica's robust Anatomic Pathology workflow management software, HALO AP®. This will include Paige's pan-cancer AI application developed using Paige's foundation model...

Read more

First-of-Its-Kind Study Characterizing the Mechanism of Template Switching With Ultraprocessive Reverse Transcriptase Enzymes

August 27, 2024 7:00 AM

BRANFORD, CT / ACCESSWIRE / August 27, 2024 / A new study demonstrates a significant advancement in our understanding of the template switching mechanism of reverse transcriptases (RTs) that is widely adopted to streamline RNA sequencing library preparation. The paper, Characterization and implementation of the MarathonRT template-switching reaction to expand the capabilities of RNA-Seq, just published in the RNA Society journal RNA, details the...

Read more

FluoGuide Appoints Jens Ellrich as Chief Medical Officer

August 26, 2024 3:20 AM

KØBENHAVN, DENMARK / ACCESSWIRE / August 26, 2024 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, announces the appointment of Jens Ellrich as Chief Medical Officer, effective November 1, 2024.Jens Ellrich, a German physician and medical scientist, brings over 30 years of extensive experience in translational neuroscience, medical devices,...

Read more

Ondine Biomedical Inc - Steriwave in all British Columbia Health Authorities

August 23, 2024 2:00 AM

VANCOUVER, BC / ACCESSWIRE / August 23, 2024 / Ondine Biomedical Inc. (LON:OBI), a leading provider of light-activated antimicrobial technology to prevent and treat hospital infections, is pleased to announce that Steriwave® nasal decolonization is now being used in all five of British Columbia's health authorities. This deployment signals Ondine's increasingly strong presence across the Canadian healthcare system.As of 21 August 2024, the...

Read more

Vibrant Wellness Advances Food Sensitivity Research With New Clinical Trial

August 22, 2024 11:00 AM

Pioneering Study Aims to Inspire Further Research into Food Sensitivity TestingSANTA CLARA, CA / ACCESSWIRE / August 22, 2024 / Vibrant Wellness, a leader in specialty lab testing, announced the release of new research on food sensitivity, highlighting their ongoing commitment to personalized wellness and longevity. The study, currently in preprint and awaiting peer-review, is a critical step toward remedying the need for more research in the...

Read more

MRES: M2Bio Food and Beverage Refocuses Strategy: Expanding Beyond CBD to Reach Global Consumers

August 22, 2024 10:00 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / August 22, 2024 / The Institute of Biomedical Research Corp. (OTC PINK:MRES), a pioneering nutraceutical biotechnology company that delves into the innovative realm of plant-based medicines, healthy food products, and sustainable packaging solutions, is pleased to announce the following updates with its M2Bio Food and Beverage division: M2Bio Food and Beverage, known for its premium, healthy, and...

Read more

Interim Report April-June 2024

August 22, 2024 2:30 AM

STOCKHOLM, SE / ACCESSWIRE / August 22, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, August 22, 2024- Vicore Pharma Holding AB (STO: VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for second quarter 2024. "This quarter, we are excited to report promising results from our Phase 2a trial evaluating buloxibutid in patients with...

Read more

Asia Green Biotechnology Corp. Announces Termination of Letter of Intent

August 21, 2024 6:55 PM

CALGARY, AB / ACCESSWIRE / August 21, 2024 / Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announced today that it has elected to the terminate the previously announced agreement dated February 9, 2024, pursuant to which the Company was to acquire all of the issued and outstanding shares in two private companies being Burton Growers Ltd. and Green-Sight Agri-Holdings Inc.Management of Asia Green has cited delays in obtaining...

Read more

CB Scientific, Inc. Announces Voluntary Delisting from OTCQB Venture Market

August 20, 2024 10:30 AM

LAS VEGAS, NV / ACCESSWIRE / August 20, 2024 / CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company"), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products and services, announced today that the Company is voluntarily delisting its common stock ("Common Stock") from trading on the OTCQB Venture Market. Delisting from the OTCQB Venture Market will have no impact on Company's Common Shares which...

Read more

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

August 19, 2024 9:00 AM

30 of a projected 39 patients have been enrolled in the clinical trial to date, including a monotherapy arm with KVA12123 and a combination arm utilizing KVA12123 together with Merck's anti-PD1 therapy, KEYTRUDA® (pembrolizumab)Kineta anticipates the trial to be fully enrolled by the end of 2024TAMPA, FL and SAN DIEGO, CA / ACCESSWIRE / August 19, 2024 / TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company...

Read more

uBriGene Biosciences Congratulates Strategic Partner InnoVec Biotherapeutics on FDA Clearance of IND for IVB103, an AAV-Based Gene Therapy

August 19, 2024 7:00 AM

-Super Speed of Only Nine MonthsGERMANTOWN, MD / ACCESSWIRE / August 19, 2024 / uBriGene Biosciences (uBriGene), a global CDMO leader, is excited to announce that its strategic partner, InnoVec Biotherapeutics, has received FDA clearance for its Investigational New Drug (IND) application for IVB103, an AAV-based gene therapy for neovascular age-related macular degeneration (nAMD). This crucial nod from the FDA marks the official launch of IVB103...

Read more

Tanvex BioPharma USA, Inc. Achieves Dual U.S. Regulatory Milestones: FDA Approves Nypozi(TM) and FDA Accepts Biosimilar Biologics License Application for TX-05

August 19, 2024 7:00 AM

FDA Approval of Nypozi™ and FDA BLA Acceptance of TX-05 Further Validates Tanvex's Expertise in Biologics Development and Manufacturing.SAN DIEGO, CA / ACCESSWIRE / August 19, 2024 / Tanvex BioPharma USA, Inc. ("Tanvex" or the "Company"), a contract development and manufacturing organization (CDMO) for biologics and a biosimilars products company, recently announced that the U.S. Food and Drug Administration (FDA) approved NYPOZI™...

Read more

Notice of Annual General Meeting in Biovica International AB

August 16, 2024 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / August 16, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the annual general meeting to be held on Tuesday 17 September 2024, at 10.00 CET in Conference Hubben's premises on Dag Hammarskjölds Väg 38 in Uppsala.Right to attend the general meeting Shareholders wishing to attend the annual...

Read more

Cadiz to Present at the Q3 Virtual Investor Summit Microcap Event

August 15, 2024 6:00 PM

NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Cadiz, Inc. (NASDAQ:CDZI)(NASDAQ:CDZIP) ("Cadiz" or the "Company"), a California water solutions company, today announced that management will present virtually at the Investor Summit Microcap Event on Tuesday, August 20, 2024. The Company will be available for 1-on-1 meetings throughout the day in addition to their presentation.Event: Q3 Investor SummitDate: August 20, 2024Presentation Time: 9:30 am...

Read more

OS Therapies Reports Second Quarter 2024 Financial Results

August 15, 2024 8:30 AM

OS Therapies, Inc. (NYSE American:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today reported financial results for the second quarter of 2024 ended June 30, 2024.As of the date of our successful initial public offering (IPO) that occurred on July 31, 2024 on the NYSE American stock exchange, the Company successfully converted all of its outstanding preferred shares and...

Read more

Indica Labs Announces Suite of HALO AI Apps to Power Life Sciences Image Analysis Workflows

August 15, 2024 8:00 AM

Indica Labs today announces expansion of AI capabilities for life science with the launch of HALO AI Apps, pre-trained tissue classifiers and cell phenotypers for tissue-based research applications. HALO AI Apps demonstrate powerful image analysis capabilities across a variety of tissue types out-of-the-box and can be further trained, tuned, and improved upon by customers with their own images and data. In total, 11 new apps are available with...

Read more

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

August 14, 2024 10:50 PM

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.Event: Q3 Investor SummitDate: August 20th, 2024Presentation Time: 2:00 pm ETLocation: https://www.webcaster4.com/Webcast/Page/3062/51117The theme is...

Read more